Top stories - GoINPHARMA
Friday, 14 December 2018 - 0:32

Top stories

Bausch Health (former Valeant) invests $200m in buying Synergy Pharma

Bausch Health–former Valeant–has announced it has acquired Synergy Pharma for $200m, after the company had already gone into voluntary liquidation and started filing for bankruptcy. Synergy’s key asset is surely Trulance, a therapy approved by FDA and Chinese authorities for…

Gilead turns the page

US-based biotech Gilead Sciences has announced that it has appointed veteran Daniel O’Day as next CEO. O’Day, 54, was born in the US and has been working for Roche for 30 years, in three different continents and in positions requiring…

Boehringer Ingelheim announces 327 job cuts in France

Germany-based Boehringer Ingelheim yesterday announced to French trade unions a restructuring plan including at least 327 job cuts in France. The decision addresses the need to completely reorganize Boehringer Ingelheim in France, which has 2,800 employees, many of which in…

Bacterial flora: a possible solution to cure autism

The importance of intestine flora in regulating organism’s balance and in the onset of certain diseases is drawing increasing interest among researchers. An interesting study on the issue has been conducted by a team of researchers from Baylor College of…

Fresenius lowers guidance and shares decline 15%

Germany-based group Fresenius’ CEO Stephan Sturm has announced during a conference call to investors that the management has lowered the guidance for the near future and now expects the company won’t be able to reach the sales and profit target…

AstraZeneca’s Imfinzi fails another Phase III clinical trial

Astra Zeneca CEO Pascal Soriot’s position is more and more difficult. The French manager in 2015 convinced shareholders to reject a $118bn acquisition offer by Pfizer, arguing that independence would mean higher financial return to shareholders. The strategy developed by…

Excellent first trading day for Moderna Therapeutics: $604m raised

Biotech Moderna Therapeutics yesterday made its IPO (Nasdaq),an event watched closely by analysts and investors, being the largest IPO ever from a biotech group.  Moderna’s listing was a success for its management: 26.3m shares were sold at $23 per share,…

Sanofi announces 670 job cuts in France

Sanofi France’s head Guillaume Leroy yesterday assembled the three French trade unions and informed them that the group intends to cut as many as 670 jobs in France before 2020. Cuts will mainly affect IT Service employees, but also HR…

Japan’s Taisho submits its offer to buy BMS’ Upsa (€1bn)

Italian daily Il Messaggero some days ago reported 4 bids for France-based Upsa, put up for sale by US-based group Bristol-Myers Squibb. The article added that pharmaceutical group Angelini made a more profitable bid than private equities PAI Partners and…

GSK acquires Tesaro for $5.1bn

After having announced job cuts, reorganizing plans and pipeline rationalization for countless times, GlaxoSmithKline’s CEO Emma Walmsley today announced, as trading started in Europe, her first acquisition. Indeed, GSK informed it has acquired US-based biotech Tesaro for $5.1bn in cash….

Gilead reports new data on efficacy of CAR-T therapy Yescarta

Gilead has reported results from ZUMA-1 clinical trial, designed to assess the breakthrough investigational therapy Yescarta (axicabtagene ciloleucel), on patients with large B-cell lymphoma. The treatment has been developed by Kite, the biotech acquired by Gilead in 2017. The trial…

Angelini most likely buyer of Upsa (Bristol-Myers Squibb)

Italian daily Il Messaggero today has reported that Angelini is the most likely candidate to acquire its French competitor Upsa, belonging to US-based Bristol-Myers Squibb. The article mentions as sources the banks hired to manage the transaction. Four companies have…

Bayer announces 12,000 job cuts globally

Germany-based group Bayer today has announced in a press release that it will cut as many as 12,000 jobs all over the world before 2021 in order to improve its profitability. The job cuts will account for almost 10% of…

Gilead can now attempt at takeover of Galapagos

The Dutch economic and financial daily Het Financieele Dagblad today has reviewed the press release issued by Belgian-Dutch biotech company Galapagos to announce that Van Herk Investments’ stake in the company has decreased to 9.91% due to dilution. As a…

Excellent Phase III results for Vertex’s new cystic fibrosis therapy

Boston, US-based Vertex Pharmaceuticals today has announced extremely positive results from two Phase III clinical trials assessing VX-659 on patients with cystic fibrosis. The results show that patients treated with VX-659 have lung functionality improved by 14% and good therapy…

Aimmune fails to convince investors with peanut allergy treatment

The prestigious New England Journal of Medicine has published today results from the Phase III PALISADE clinical trial, aimed at assessing the new oral immunotherapy AR101, developed by biotech Aimmune Therapeutics, in desensitizing children with peanut allergies. The results have…

Boston Scientific announces acquisition of BTG for GBP3.3bn

US-based medical devices producer Boston Scientific has acquired its UK-based competitor BTG for GBP3.3bn. Boston Scientific has valued BTG 840p per share, which means a premium 36% over Monday’s closing price. The move will strengthen Boston Scientific’s position in the…

First rumors about radical top management reshuffle at Astra Zeneca

The Sunday Times yesterday reported that AstraZeneca has started working on a replacement plan for CEO Pascal Soriot and CFO Marc Dunoyerl, due to pressure by some main shareholders, dissatisfied with the French manager’s work. The British weekly mentions Mene…

Renewed talk about Gilead seeking to acquire Tesaro ($2bn)

Bloomberg has reported that Tesaro is seeking a sale, which was enough for its shares to be up over 30% as trading closed last Friday. According to the report, some potential acquirers have already stepped up, and the company’s management…

Time for radical change at Novartis

Swiss daily newspaper Tagesanzeiger reported that Novartis – with a CHF223bn market capitalization – aims at splitting Sandoz division from the rest of the company, thus making it completely independent. New 42-year-old CEO Vas Narasimhan reportedly said so while dining…

Flat quarter for Bayer, shares drop 3%

Chemical-pharmaceutical group Bayer has surprised markets with a fairly flat quarter, which has caused its shares to plunge, losing 3% over few hours (Frankfurt). The Leverkusen-based group’s management links the poor performance to a fairly negative currency impact (strong dollar),…

AstraZeneca sells Synagis for 1.5 billion dollars

AstraZeneca’s shares rose over 1% today (London) as the group led by Pascal Soriot announced that it has sold to Swedish Orphan Biovitrum AB (SOBI) the rights to market its therapy for respiratory diseases Synagis in the US . The…